Related Experiment Videos
Hypocholesterolemia in acute myelogenous leukemia
J C Reverter1, J Sierra, J M Martí-Tutusaus
1Postgraduate School of Hematology Ferreras Valenti, Hospital Clinic, University of Barcelona, Spain.
European Journal of Haematology
|October 1, 1988
Summary
Hypocholesterolemia is common in acute myelogenous leukemia (AML) at diagnosis, particularly with high white blood cell counts. Cholesterol levels often normalize during remission, suggesting a link to tumor burden in AML.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Background:
- Acute myelogenous leukemia (AML) is a heterogeneous hematologic malignancy.
- Plasma-cholesterol levels can be affected by various physiological and pathological conditions.
- Understanding metabolic alterations in AML is crucial for patient management.
Purpose of the Study:
- To investigate plasma-cholesterol concentrations in patients with acute myelogenous leukemia (AML).
- To identify correlations between hypocholesterolemia and clinical, hematologic, and biochemical parameters in AML.
- To assess the impact of remission on cholesterol levels in AML patients.
Main Methods:
- Plasma-cholesterol levels were measured in 85 AML patients at diagnosis.
- Measurements were repeated in 28 patients during remission.
- Statistical analyses were performed to correlate cholesterol with clinical and hematologic data, including FAB subtypes and leukocyte counts.
Main Results:
- The mean plasma-cholesterol concentration at diagnosis was 3.95 mmol/l, with 55.3% of patients exhibiting hypocholesterolemia (< 3.87 mmol/l).
- Hypocholesterolemia was significantly correlated with high leukocyte counts and specific French-American-British (FAB) subtypes (monocytic component).
- Remission was associated with increased cholesterol levels in patients with initial hypocholesterolemia or high leukocyte counts.
Conclusions:
- Initial hypocholesterolemia in AML appears to be related to the tumor mass at diagnosis.
- Leukocyte count and FAB subtype are independent predictors of low cholesterol levels in AML.
- Cholesterol normalization during remission supports the hypothesis of a tumor-related metabolic derangement in AML.